Chan Andrew C. 4
4 · Corvus Pharmaceuticals, Inc. · Filed Apr 27, 2026
Research Summary
AI-generated summary of this filing
Corvus Pharmaceuticals Director Andrew Chan Receives 30,000-Share Award
What Happened Andrew C. Chan, a director of Corvus Pharmaceuticals (CRVS), was granted a 30,000-share derivative award on April 23, 2026. The filing reports an acquisition at $0.00 per share (no upfront cash value reported) — this is an award/grant (not an open-market purchase or sale).
Key Details
- Transaction date: 2026-04-23; reported on Form 4 filed 2026-04-27 (timely).
- Transaction type: Award/Grant of a derivative instrument (code A), 30,000 shares, reported price $0.00.
- Shares owned after transaction: Not specified in the filing.
- Footnote: The underlying shares vest and become exercisable as to one-third of the shares on each annual anniversary beginning April 23, 2026, subject to continued service (3-year time-based vesting).
- No 10b5-1 plan, tax-withholding, or late-filing flags noted in this filing.
Context This was a compensation-related equity award to a director rather than a market purchase or sale. Because the award vests over time, the shares are not immediately available; future filings will disclose exercises or sales if/when they occur. Such grants are common for board compensation and should be viewed as part of executive/director pay rather than a direct buy/sell signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-04-23+30,000→ 30,000 totalExercise: $16.02Exp: 2036-04-23→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 23, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.